The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. 
Introduction
Sudden cardiac death (SCD) claims the lives of approximately 50 to 100 per 100 000 people in North America and Europe. 2 -4 The risk of SCD has been shown to be highest early after myocardial infarction (MI) 5 ; however, uncertainty remains regarding the risk of SCD following an acute heart failure (HF) hospital admission.
Heart failure practice guidelines recommend implanting an implantable cardioverter-defibrillator (ICD) in patients who have a left ventricular ejection fraction (LVEF) ≤35% despite optimal medical therapy for 90 days. 6 This period of optimal medical therapy is mandated to allow for potential improvement in LVEF such that ICD implantation could be avoided. However, this approach leaves a subset of HF patients at risk for arrhythmic death, while medical therapy is being optimized. The EVEREST trial of acute HF patients showed that SCD accounted for 26% of all deaths, and 15% of the SCD events occurred within 30 days of randomization. An additional 10% of SCD occurred between 31 and 60 days of randomization. 7 Thus, there is a need to identify predictors of increased SCD risk following acute HF hospital admission. Currently, there is not a validated tool to risk stratify patients for SCD after acute HF hospital admission.
We conducted this study to assess the incidence of SCD in patients following acute HF hospital admission, to identify clinical predictors of SCD in HF patients, and to understand the association of resuscitated SCD (RSCD) and ventricular tachycardia (VT)/aborted ventricular fibrillation (VF) with subsequent all-cause mortality.
Methods

Study patients
The design and results of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial have been previously described. 8 Briefly, ASCEND-HF included 7141 patients hospitalized for acute HF at 398 sites around the world and randomized to nesiritide vs. placebo. Patients were enrolled in ASCEND-HF from May 2007 through August 2010 if they had an acute HF hospital admission in the setting of a reduced or preserved LVEF. The co-primary endpoints for the ASCEND-HF trial were: (i) the change in self-reported dyspnoea at 6 and 24 h after study drug initiation, and (ii) the composite of HF rehospitalization and all-cause mortality through 30 days after randomization. 9 The present study is a post-hoc analysis of 7011 patients randomized in the ASCEND-HF trial with available data on SCD, and patients with ICDs in situ at the time of randomization were included in the analysis.
Endpoints
An independent, blinded clinical events committee adjudicated outcomes including SCD, RSCD, and sustained VT/VF through 30 days after randomization. SCD was defined as death that occurred unexpectedly in a previously stable patient and was: (i) witnessed and instantaneous without new or worsening symptoms and also in the absence of progressive circulatory failure lasting for ≥60 min; (ii) witnessed within 60 min of the onset of new or worsening symptoms unless a cause other than cardiac was obvious; (iii) witnessed and attributed to an identified arrhythmia on an electrocardiogram or a monitor; (iv) in patients with attempted resuscitation from cardiac arrest in the absence of pre-existing circulatory failure or other causes of death, including MI, and who died during the attempted resuscitation, within 24 h, or without re-gaining consciousness; or (v) VT/VF was defined as a documented VT/VF episode that required an intervention but did not result in SCD. In the present study, these three events were combined to form a composite endpoint to have sufficient power to establish a multivariable model. Patients could have more than one event within 30 days of randomization. All-cause mortality was reported out to 180 days after randomization; however, cause of death was not adjudicated between 30 and 180 days.
Statistical analysis
Continuous variables were reported as medians (25th and 75th percentiles), and categorical variables were reported as counts (percentages). A logistic regression model identified factors associated with the composite endpoint of SCD, RSCD, or VT/VF. A backward selection, stepwise model was used with selection criteria of a P-value of 0.1 for entry into the model. Most candidate variables (see supplementary Methods S1 online) were previously used in the death and rehospitalization models from ASCEND-HF. 10 Missing variables were imputed through multiple imputation by logistic regression model using 25 imputed datasets. Missingness for variables was <1% with the exception of blood urea nitrogen (8%), creatinine (5%), sodium (6%), potassium (7%), haemoglobin (8%), and New York Heart Association (NYHA) class (18%). A sensitivity analysis was performed on the post-discharge composite endpoint by re-running the logistic regression model after excluding patients with an in-hospital event (n = 66).
The rates of SCD, RSCD, VT/VF, and the composite endpoint were calculated by 30-day Kaplan-Meier rates. Sensitivity analyses reported the 30-day events for patients with preserved LVEF (≥50%) vs. reduced LVEF (<50%), as well as in-hospital vs. out-of-hospital events. Because a history of VT was the characteristic most strongly associated with the composite endpoint, the Kaplan-Meier event rates were stratified by a history of VT, as an exploratory post-hoc analysis. A Kaplan-Meier event curve was generated for patients with RSCD and patients with VT/VF, evaluating the 180-day all-cause mortality as a landmark analysis from the time of the index non-fatal event. The Kaplan-Meier 180-day all-cause mortality was generated for patients with no RSCD or VT/VF, as a comparator group. In a multivariable Cox model, RSCD and VT/VF were used as time-dependent variables to assess the association with 180-day all-cause mortality. The adjustment variables in this model were similar to the variables in the 180-day all-cause mortality model from the overall ASCEND-HF trial (see supplementary Methods S2 online).
All patients provided written informed consent prior to randomization. The Duke Clinical Research Institute (Durham, NC, USA) coordinated the trial and performed the statistical analyses for this manuscript. All statistical analyses were performed with SAS software, version 9.2 (SAS Institute, Cary, NC, USA). The Institutional Review Board of Duke University approved this study. Univariate analyses demonstrated that patients who experienced the composite endpoint were less likely female (22% vs. 35%, P = 0.003) and more likely to have had an elevated troponin at the time of HF admission (41% vs. 23%, P = 0.002), a history of VT (19% vs. 9%, P < 0.001), and a history of ICD or biventricular pacemaker (24% vs. 16%, P = 0.019 or 15% vs. 9%, P = 0.019, respectively) ( Table 1 ). The 1136 patients (16%) with ICDs in situ accounted for 24% (29 events) of all composite events, while SCD accounted for 17% (5/29) of the events in patients with ICDs, as compared with 41% (38/92) of the composite events among patients without an ICD (n = 5875). There were 954 patients (14%) with a preserved LVEF (≥50%) and 6057 patients (86%) with a reduced LVEF (<50%), and 90% of the composite events (109/121) were seen in the reduced LVEF population.
Patients that had a composite event prior to discharge (n = 66) were similar to patients without a composite event prior to discharge but with an event post-discharge; however, patients with an event prior to discharge tended to have a higher body mass index (29 vs. 25 kg/m 2 , P = 0.007), higher heart rate (89 vs. 80 b.p.m., P = 0.002), and a history of VT (26% vs. 11%, P = 0.038) (supplementary material online, Table S1 ). duration on the baseline electrocardiogram was also associated with SCD, RSCD, or VT/VF, as every 10% increase in QRS duration was associated with 10% higher odds of the composite endpoint (OR 1.10 for every 10% increase in QRS duration, 95% CI 1.03-1.17, P = 0.005). The two additional baseline characteristics associated with having the composite endpoint were male sex and chronic obstructive pulmonary disease; higher heart rate at baseline, beta-blocker use, and normal LVEF were not associated with the composite endpoint ( Table 2 ). The c-statistic for the multivariable model was 0.643. A sensitivity analysis found that an increase in QRS duration remained associated with SCD, RSCD, or VT/VF post-discharge, among patients without an in-hospital event (OR 1.12 for every 10% increase in QRS duration, 95% CI 1.02-1.23) (supplementary material online, Table S2 ).
Event rates
Ten patients had more than one event with 30-day Kaplan-Meier event rates of 0.6% for SCD (95% CI 0.5%-0.9%, n = 43), 0.4% for RSCD (95% CI 0.2%-0.5%, n = 24), and 0.9% for VT/VF (95% CI 0.7%-1.2%, n = 64) (Figure 1) . One-third (0.6% event rate) and one-half (0.9% event rate) of the composite events took place within the first 5 and 10 days, respectively, and no SCD events occurred until day 6, while the SCD event rate increased linearly between 6 and 30 days (Figure 2) . Of the 43 SCD events, 42 (98%) of these events occurred after hospital discharge. This contrasts with the 17 (71%) RSCD and 53 (83%) VT/VF events that took place in the hospital prior to discharge. Patients with a history of VT experienced the composite endpoint of SCD/RSCD/VT/VF at a 30-day rate of 3.8% vs. 1.6% among patients with no history of VT ( Figure 3) . The 30-day rate of SCD or RSCD was 0.9%, and the 30-day rate of all-cause mortality rate was 3.8%, while SCD accounted for 17% of the all-cause deaths. A sensitivity analysis of events among patients with reduced vs. preserved LVEF found similar 30-day composite event rates (1.8% for reduced vs. 1.3% for preserved, P = 0.23) (supplementary material online, Figure S1 ). The 30-day rates of SCD were also similar for patients with reduced (0.6%) vs. preserved (0.8%) LVEF (P = 0.61) (supplementary material online, Figure S2 ). The 30-day rate of VT/VF was higher among patients with reduced LVEF (1.1%) relative to patients with preserved LVEF (0.1%, P = 0.005) (supplementary material online, Figure S3) .
The rate of all-cause mortality in the ASCEND-HF trial between 30 days and 180 days was 9.3% (95% CI 8.6%-10.0%), while the rate of all-cause mortality from the time of a RSCD/VT/VF event through 180 days after randomization was 47.0% (95% CI 37.0%-58.2%). A RSCD/VT/VF event was independently associated with a higher 180-day all-cause mortality after multivariable adjustment [adjusted hazard ratio (HR) 6.6, 95% CI 4.8-9.1, P < 0.0001]. In the landmark analysis, approximately two-thirds of the mortality among RSCD/VT/VF patients was seen within the first 10 days of the initial event (Figure 4 ).
Discussion
The Kaplan-Meier event rate of 30-day SCD, RSCD, or VT/VF was 1.8% in the ASCEND-HF trial; nearly one in six deaths within 30 days of HF hospital admission was due to SCD. Patients at highest risk for the composite endpoint of SCD/RSCD/VT/VF had a history of VT, a wider QRS complex at baseline, and underlying lung disease. The occurrence of RSCD or VT/VF within 30 days of HF hospital admission was strongly predictive of increased 6-month mortality.
. The first 30 days after MI in HF patients and after acute HF hospitalization have been identified as the highest risk period for SCD. 5, 7 The rate of sustained VT/VF within 30 days of HF hospitalization was 0.9%. This rate is lower than the 1.5% rate of 30-day VT/VF identified in a non-ST-elevation MI population.
11 The combined 30-day event rate for SCD or RSCD in ASCEND-HF of 0.9% was lower than the 1.4% rate of 30-day SCD or RSCD in Valsartan in Acute Myocardial Infarction Trial (VALIANT), which was likely due to a higher rate of ischaemic cardiomyopathy in VALIANT (100% in VALIANT vs. 60% in ASCEND-HF). 5 In the present study, nearly one in six deaths within 30 days of acute HF hospital admission were due to SCD, which was similar to the approximately one in seven deaths attributed to 30-day SCD in the EVEREST trial. 7 In EVEREST, SCD was the second most common mode of death (25%) behind HF (41%) with a median follow-up of 10 months. 7 The rate of SCD within clinical trials of ambulatory HF patients has decreased over time from a 30-day incidence of 1.0% to 0.3-0.4%, as medical regimens have improved. 12 The 0.6% incidence of 30-day SCD in ASCEND-HF was nearly double the rate of the contemporary ambulatory HF clinical trials 12 ; however, the ASCEND-HF population is likely at higher risk because it is an acute HF population.
Predictors of SCD, RSCD, or VT/VF may help risk stratify patients at the time of an acute HF hospital admission. History of VT, wider QRS, and underlying lung disease were most strongly associated with the composite endpoint of SCD, RSCD and VT/VF at 30 days, and male sex was an additional predictor. None of these variables overlapped with the variables associated with 30-day morality within ASCEND-HF: age, blood urea nitrogen, sodium, systolic blood pressure, and baseline dyspnoea. 10 Similarly, none of the variables identified in the current analysis overlapped with the predictive models of 30-day sustained VT/VF in a non-ST-elevation MI population or of 30-day SCD in VALIANT. 11, 13 Prior work evaluating a chronic HF population identified male sex as a factor associated with SCD (OR 1.4, P = 0.002), as was seen in the current analysis (OR 1.7); however, additional factors including age, diabetes, LVEF, systolic blood pressure, creatinine, sodium, NYHA class, body mass index, and digoxin use were also associated with SCD in the chronic HF population.
14 Differences between the chronic HF model and the ASCEND-HF model may be related to the differences between outcomes in patients with acute decompensated vs. chronic HF, although history of VT, QRS width, and underlying lung disease were not variables included in the model for the chronic HF population.
14 Chronic obstructive pulmonary disease has been associated with SCD in a general patient population, and the mechanism may be related to hypoxia or to the limited physiologic reserve available under stress.
15,16 QRS duration has been identified as a potential predictor of SCD, 17, 18 and QRS duration has been associated with risk of ICD shock.
19
Patients with a preserved LVEF (≥50%) represented 14% of the patients in ASCEND-HF, and these patients accumulated a proportionate number of composite 30-day endpoint events (10%). Patients with a preserved LVEF compared to patients with a reduced LVEF had a similar 30-day composite event rate (1.3% vs. 1.8%, P = 0.23) and SCD event rate (0.8% vs. 0.6%, P = 0.30). The multivariable model demonstrated that preserved LVEF was not 23 It is likely that many of the same mechanisms that affect SCD in patients with reduced LVEF also affect patients with preserved LVEF, including neurohormonal abnormalities, autonomic imbalances, and ischaemia. were not adjudicated for the mode of death, but patients with a history of RSCD have high rates of SCD. 25 In addition, data from the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial showed that with 18 months of follow-up 45% of the deaths in the antiarrhythmic medication arm were due to arrhythmic death, which was similar to the 37-39% of deaths that were due to SCD in the most recent ambulatory HF clinical trials. 12, 26 Despite the strong association with longer-term mortality, it remains unknown as to whether any interventions would improve survival in these patients.
Clinical implications
Patients with characteristics associated with higher rates of SCD, RSCD, or sustained VT/VF should be followed closely with S.D. Pokorney et al. consideration given to minimizing their risk of an arrhythmic event. Patients admitted to the hospital for acute decompensated HF should be considered for telemetry monitoring during their hospitalization, given the risks of ventricular arrhythmias. Early follow-up after HF hospitalization has been previously associated with lower HF rehospitalization, 27 and early cardiology follow-up has been associated with higher rates of ICD implantation in patients after MI. 28 
12
Use of beta-blockers, 29 angiotensin II receptor blockers, 21 and mineralocorticoid receptor antagonists 30 have all been shown to reduce SCD, so use of guideline-directed HF medical therapy is important in patients hospitalized for decompensated HF. Additional studies are needed to validate the findings regarding the risk of arrhythmic events early after HF hospitalization, to further risk stratify patients with acute HF exacerbations, and to understand the likelihood of LVEF recovery in this patient population. Further investigation is needed to understand how to improve survival among patients with RSCD or sustained VT/VF, including use of antiarrhythmic medications or VT ablation.
Limitations
There are several important limitations to this analysis. In order to allow an adequate event count to perform multivariable modelling, a composite endpoint was created for SCD, RSCD, or VT/VF; however, the severity of these three events is not equivalent. The use of ICDs and cardiac resynchronization therapy in the ASCEND-HF trial population was low. The SCD events may not all be arrhythmic death events, as MI and cerebrovascular events may also be classified as SCD. Adjudicated events were only available out to 30 days, and it would be valuable to understand these event rates out to 90 days. This is especially important for new onset HF patients or HF patients not on optimal medical therapy at the time of their hospitalization, as the current guidelines recommend 90 days of optimal medical therapy prior to ICD implantation. Cause of death between 30 days and 180 days was not adjudicated.
Conclusion
Among patients admitted for acute HF, approximately 2% experienced SCD, RSCD, or VT/VF within 30 days. A history of VT, wider QRS duration, and underlying lung disease were the most significant predictors of the 30-day composite endpoint. Further research is needed to understand how to best protect HF patients against arrhythmic events early after HF hospitalization.
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